Collectively, our data showed that changes in the gut microbiome affect the glycerophospholipid metabolic pathway, thereby regulating the therapeutic potential of PD-1 antibody in the immunotherapy of MSS-type CRC tumor-bearing mice. Here, PDCD1 is linked to colorectal carcinoma.